Jaka jest cena za Thalia Therapeutics Plc (THAT)

Cena za Thalia Therapeutics Plc (THAT) wynosi $0.00918474

Jaka jest kapitalizacja rynkowa dla Thalia Therapeutics Plc (THAT)

Kapitalizacja rynkowa dla Thalia Therapeutics Plc (THAT) wynosi $76.44K

Przychody Thalia Therapeutics Plc (THAT)

Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.

Rok	Przychody	Zmień
Za mało danych dla podanych dat.

Rok

Przychody

Zmień

Za mało danych dla podanych dat.

Firma	Przychody	Różnica w przychodach	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$10.11B	-	BE

Firma

Przychody

Różnica w przychodach

Kraj